生物制剂治疗儿童自身免疫性疾病的研究进展
Research Progress in Biologic Agents for Treating Autoimmune Diseases in Children
DOI: 10.12677/acm.2025.1551441, PDF,   
作者: 焦晓宇：山东大学齐鲁医院儿科，山东 济南
关键词: 自身免疫性疾病；生物制剂；临床试验；儿童；Autoimmune Diseases； Biologic Agents； Clinical Trails； Children
摘要: 自身免疫性疾病(Autoimmune diseases, AIDs)是一组免疫系统对自身抗原产生持续迁延的免疫应答的疾病。近年来，儿童自身免疫性疾病的发病率逐渐升高，危害儿童身体健康。传统治疗方案以糖皮质激素和免疫抑制剂为主，但部分患者治疗后疾病控制效果不佳、复发率高。随着生物制剂在临床上的应用，AIDs患者的治疗效果在一定程度上得到了改善。本文阐述AIDs种生物制剂的治疗现状与进展，对临床医生精准施用方案、控制患儿病情、改善治疗效果及预后等方面具有深远意义。
Abstract: Autoimmune diseases (AIDs) are a group of disorders characterized by persistent and prolonged immune responses against self-antigens. In recent years, the incidence of autoimmune diseases in children has gradually increased, posing significant risks to their health. Traditional treatment regimens primarily rely on glucocorticoids and immunosuppressants, but some patients exhibit poor disease control and high relapse rates after therapy. With the clinical application of biologic agents, the therapeutic outcomes for AIDs patients have improved to some extent. This article reviews the current status and advances in biological therapies for AIDs, which holds profound implications for clinicians in optimizing treatment strategies, achieving disease control, improving therapeutic efficacy, and enhancing prognosis in pediatric patients.
文章引用：焦晓宇. 生物制剂治疗儿童自身免疫性疾病的研究进展[J]. 临床医学进展, 2025, 15(5): 831-839. https://doi.org/10.12677/acm.2025.1551441

参考文献

[1] Pisetsky, D.S. (2023) Pathogenesis of Autoimmune Disease. Nature Reviews Nephrology, 19, 509-524. [Google Scholar] [CrossRef] [PubMed]
[2] Ludwig, R.J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S.M., et al. (2017) Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 8, Article 603. [Google Scholar] [CrossRef] [PubMed]
[3] Eaton, W.W., Pedersen, M.G., Atladóttir, H.Ó., Gregory, P.E., Rose, N.R. and Mortensen, P.B. (2010) The Prevalence of 30 ICD-10 Autoimmune Diseases in Denmark. Immunologic Research, 47, 228-231. [Google Scholar] [CrossRef] [PubMed]
[4] Eaton, W.W., Rose, N.R., Kalaydjian, A., Pedersen, M.G. and Mortensen, P.B. (2007) Epidemiology of Autoimmune Diseases in Denmark. Journal of Autoimmunity, 29, 1-9. [Google Scholar] [CrossRef] [PubMed]
[5] Sardu, C., Cocco, E., Mereu, A., Massa, R., Cuccu, A., Marrosu, M.G., et al. (2012) Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. PLOS ONE, 7, e32487. [Google Scholar] [CrossRef] [PubMed]
[6] Saougou, I.G., Markatseli, T.E., Voulgari, P.V. and Drosos, A.A. (2021) Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis. Current Rheumatology Reviews, 17, 41-57. [Google Scholar] [CrossRef] [PubMed]
[7] Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., FitzGerald, J.D., et al. (2012) American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care & Research, 64, 797-808. [Google Scholar] [CrossRef] [PubMed]
[8] Schioppo, T. and Ingegnoli, F. (2017) Current Perspective on Rituximab in Rheumatic Diseases. Drug Design, Development and Therapy, 11, 2891-2904. [Google Scholar] [CrossRef] [PubMed]
[9] Reddy, V., Cambridge, G., Isenberg, D.A., Glennie, M.J., Cragg, M.S. and Leandro, M. (2015) Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Arthritis & Rheumatology, 67, 2046-2055. [Google Scholar] [CrossRef] [PubMed]
[10] Watson, L., Beresford, M.W., Maynes, C., Pilkington, C., Marks, S.D., Glackin, Y., et al. (2014) The Indications, Efficacy and Adverse Events of Rituximab in a Large Cohort of Patients with Juvenile-Onset SLE. Lupus, 24, 10-17. [Google Scholar] [CrossRef] [PubMed]
[11] Mahmoud, I., Jellouli, M., Boukhris, I., Charfi, R., Ben Tekaya, A., Saidane, O., et al. (2017) Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. The Journal of Pediatrics, 187, 213-219.E2. [Google Scholar] [CrossRef] [PubMed]
[12] Lehman, T.J., Singh, C., Ramanathan, A., Alperin, R., Adams, A., Barinstein, L., et al. (2014) Prolonged Improvement of Childhood Onset Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide. Pediatric Rheumatology, 12, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
[13] AlE’ed, A., AlSonbul, A. and Al-Mayouf, S.M. (2013) Safety and Efficacy of Combined Cyclophosphamide and Rituximab Treatment in Recalcitrant Childhood Lupus. Rheumatology International, 34, 529-533. [Google Scholar] [CrossRef] [PubMed]
[14] Hogan, J., Godron, A., Baudouin, V., Kwon, T., Harambat, J., Deschênes, G., et al. (2017) Combination Therapy of Rituximab and Mycophenolate Mofetil in Childhood Lupus Nephritis. Pediatric Nephrology, 33, 111-116. [Google Scholar] [CrossRef] [PubMed]
[15] Kamei, K., Ishikura, K., Sako, M., Ito, S., Nozu, K. and Iijima, K. (2018) Rituximab Therapy for Refractory Steroid-Resistant Nephrotic Syndrome in Children. Pediatric Nephrology, 35, 17-24. [Google Scholar] [CrossRef] [PubMed]
[16] Kallash, M., Smoyer, W.E. and Mahan, J.D. (2019) Rituximab Use in the Management of Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 7, Article 178. [Google Scholar] [CrossRef] [PubMed]
[17] 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016) [J]. 中华儿科杂志, 2017, 55(10): 729-734.
[18] 中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版) [J]. 中华神经科杂志, 2022, 55(9): 931-949.
[19] Yang, J.H., Liu, E.N., Nguyen, L., Dunn-Pirio, A. and Graves, J.S. (2023) Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis. Neurology, 101, e2300-e2313. [Google Scholar] [CrossRef] [PubMed]
[20] Thaler, F.S., Zimmermann, L., Kammermeier, S., Strippel, C., Ringelstein, M., Kraft, A., et al. (2021) Rituximab Treatment and Long-Term Outcome of Patients with Autoimmune Encephalitis: Real-World Evidence from the GENERATE Registry. Neurology Neuroimmunology & Neuroinflammation, 8, e1088. [Google Scholar] [CrossRef] 
[21] Titulaer, M.J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., et al. (2013) Treatment and Prognostic Factors for Long-Term Outcome in Patients with Anti-Nmda Receptor Encephalitis: An Observational Cohort Study. The Lancet Neurology, 12, 157-165. [Google Scholar] [CrossRef] [PubMed]
[22] Dörner, T., Shock, A., Goldenberg, D.M. and Lipsky, P.E. (2015) The Mechanistic Impact of CD22 Engagement with Epratuzumab on B Cell Function: Implications for the Treatment of Systemic Lupus Erythematosus. Autoimmunity Reviews, 14, 1079-1086. [Google Scholar] [CrossRef] [PubMed]
[23] Clowse, M.E.B., Wallace, D.J., Furie, R.A., Petri, M.A., Pike, M.C., Leszczyński, P., et al. (2017) Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results from Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials. Arthritis & Rheumatology, 69, 362-375. [Google Scholar] [CrossRef] [PubMed]
[24] Wallace, D.J., Kalunian, K., Petri, M.A., Strand, V., Houssiau, F.A., Pike, M., et al. (2014) Efficacy and Safety of Epratuzumab in Patients with Moderate/Severe Active Systemic Lupus Erythematosus: Results from EMBLEM, a Phase Iib, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study. Annals of the Rheumatic Diseases, 73, 183-190. [Google Scholar] [CrossRef] [PubMed]
[25] Wallace, D.J., Gordon, C., Strand, V., Hobbs, K., Petri, M., Kalunian, K., et al. (2013) Efficacy and Safety of Epratuzumab in Patients with Moderate/Severe Flaring Systemic Lupus Erythematosus: Results from Two Randomized, Double-Blind, Placebo-Controlled, Multicentre Studies (ALLEVIATE) and Follow-Up. Rheumatology, 52, 1313-1322. [Google Scholar] [CrossRef] [PubMed]
[26] 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185.
[27] Brunner, H.I., Abud-Mendoza, C., Viola, D.O., Calvo Penades, I., Levy, D., Anton, J., et al. (2020) Safety and Efficacy of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: Results from a Randomised, Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 79, 1340-1348. [Google Scholar] [CrossRef] [PubMed]
[28] 亚太医学生物免疫学会儿童过敏免疫风湿病分会(PAIRB-APAMBI)多中心研究协作组, 《中国实用儿科杂志》编辑委员会. 贝利尤单抗治疗中国儿童系统性红斑狼疮28周有效性和安全性分析: 一项回顾性多中心真实世界的初步研究[J]. 中国实用儿科杂志, 2021, 36(11): 858-868.
[29] Gong, Y., Liu, S., Liu, H., Shi, Y., Li, Y., Guan, W., et al. (2024) Efficacy of Initial Combination with Belimumab in Newly Diagnosed Childhood-Onset Lupus Nephritis: A Single-Centre Historical Control Study. Lupus Science & Medicine, 11, e001350. [Google Scholar] [CrossRef] [PubMed]
[30] Romo-Tena, J., Gómez-Martín, D. and Alcocer-Varela, J. (2013) CTLA-4 and Autoimmunity: New Insights into the Dual Regulator of Tolerance. Autoimmunity Reviews, 12, 1171-1176. [Google Scholar] [CrossRef] [PubMed]
[31] Ruperto, N., Lovell, D.J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C.A., et al. (2008) Abatacept in Children with Juvenile Idiopathic Arthritis: A Randomised, Double-Blind, Placebo-Controlled Withdrawal Trial. The Lancet, 372, 383-391. [Google Scholar] [CrossRef] [PubMed]
[32] Brunner, H.I., Tzaribachev, N., Vega‐Cornejo, G., Louw, I., Berman, A., Calvo Penadés, I., et al. (2018) Subcutaneous Abatacept in Patients with Polyarticular‐Course Juvenile Idiopathic Arthritis: Results from a Phase III Open-Label Study. Arthritis & Rheumatology, 70, 1144-1154. [Google Scholar] [CrossRef] [PubMed]
[33] Ruperto, N., Lovell, D.J., Quartier, P., Paz, E., Rubio‐Pérez, N., Silva, C.A., et al. (2010) Long‐Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis & Rheumatism, 62, 1792-1802. [Google Scholar] [CrossRef] [PubMed]
[34] Brunner, H.I., Wong, R., Nys, M., Kou, T.D., Dominique, A., Martini, A., et al. (2020) Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Pediatric Drugs, 22, 653-672. [Google Scholar] [CrossRef] [PubMed]
[35] 中华医学会儿科学分会风湿病学组, 中国医师协会风湿免疫科医师分会儿科学组, 海峡两岸医药卫生交流协会风湿免疫病学专业委员会儿童学组, 等. 幼年特发性关节炎生物制剂及小分子靶向药物治疗专家共识(2022版) [J]. 中华实用儿科临床杂志, 2022, 37(14): 1066-1073.
[36] Paley, M.A., Strand, V. and Kim, A.H.J. (2017) From Mechanism to Therapies in Systemic Lupus Erythematosus. Current Opinion in Rheumatology, 29, 178-186. [Google Scholar] [CrossRef] [PubMed]
[37] Sheppard, M., Laskou, F., Stapleton, P.P., Hadavi, S. and Dasgupta, B. (2017) Tocilizumab (Actemra). Human Vaccines & Immunotherapeutics, 13, 1972-1988. [Google Scholar] [CrossRef] [PubMed]
[38] Srirangan, S. and Choy, E.H. (2010) The Role of Interleukin 6 in the Pathophysiology of Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease, 2, 247-256. [Google Scholar] [CrossRef] [PubMed]
[39] De Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., et al. (2012) Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 367, 2385-2395. [Google Scholar] [CrossRef] [PubMed]
[40] Brunner, H.I., Ruperto, N., Zuber, Z., Keane, C., Harari, O., Kenwright, A., et al. (2015) Efficacy and Safety of Tocilizumab in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis: Results from a Phase 3, Randomised, Double-Blind Withdrawal Trial. Annals of the Rheumatic Diseases, 74, 1110-1117. [Google Scholar] [CrossRef] [PubMed]
[41] 中华医学会儿科学分会免疫学组, 中华儿科杂志编辑委员会, 中国儿童风湿免疫病联盟. 中国幼年特发性关节炎诊断及治疗临床实践指南(2023版) [J]. 中华儿科杂志, 2023, 61(5): 398-411.
[42] Micheau, O. and Tschopp, J. (2003) Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes. Cell, 114, 181-190. [Google Scholar] [CrossRef] [PubMed]
[43] Ghorbaninezhad, F., Leone, P., Alemohammad, H., Najafzadeh, B., Nourbakhsh, N., Prete, M., et al. (2022) Tumor Necrosis Factor-α in Systemic Lupus Erythematosus: Structure, Function and Therapeutic Implications (Review). International Journal of Molecular Medicine, 49, Article No. 43. [Google Scholar] [CrossRef] [PubMed]
[44] Klotsche, J., Klein, A., Niewerth, M., Hoff, P., Windschall, D., Foeldvari, I., et al. (2021) Re-Treatment with Etanercept Is as Effective as the Initial Firstline Treatment in Patients with Juvenile Idiopathic Arthritis. Arthritis Research & Therapy, 23, Article No. 118. [Google Scholar] [CrossRef] [PubMed]

为你推荐